Notably, Osimertinib, a third-generation EGFR-TKI, effective against both EGFR-sensitive mutations and T790M resistance mutations, has made substantial progress in the treatment of advanced lung adenocarcinoma, especially as a first-line therapy and in the management of brain metastases [4]. The gene discussed is EGFR; the disease is lung adenocarcinoma.